Description General description A cell-permeable thiazolidinone compound that specifically inhibits the c-Myc-Max interaction, thereby preventing the transactivation of c-Myc target gene expression. Shown to inhibit tumor cell growth in a c-Myc-dependent manner both in vitro and in vivo (64 μM using c-Myc transfected Rat1a fibroblasts). A cell-permeable, thiazolidinone compound that specifically inhibits c-Myc-Max interaction, thereby preventing the transactivation of c-Myc targeted gene expression. Shown to inhibit tumor cell growth in a c-Myc-dependent manner both in vitro and in vivo (Effective concentration: 64 µM using c-Myc-transfected Rat1a fibroblasts). Packaging 10 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target c-Myc Product does not compete with ATP. Reversible: no Packaging Packaged under inert gas Warning Toxicity: Carcinogenic / Teratogenic (D) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Other Notes Yin, X., et al. 2003. Oncogene22, 6151. Legal Information Sold under license of U.S. Patent 7,026,343.